These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1988163)

  • 1. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
    Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
    Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PHA induces IL-2 receptors on B-CLL cells and is a potential biological response modifier for the LIL-2-diphtheria toxin, DAB486IL-2.
    Bulger K; Padua F; Duff R; Pihan G; Nichols J; Murphy J; McCaffrey R
    Leuk Res; 1994 Feb; 18(2):119-22. PubMed ID: 8107488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A kinetic analysis of the effects of interleukin-2 diphtheria toxin fusion protein upon activated T cells.
    Walz G; Zanker B; Murphy JR; Strom TB
    Transplantation; 1990 Jan; 49(1):198-201. PubMed ID: 2301012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
    Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
    Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells.
    Waters CA; Snider CE; Itoh K; Poisson L; Strom TB; Murphy JR; Nichols JC
    Ann N Y Acad Sci; 1991 Dec; 636():403-5. PubMed ID: 1793228
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.
    LeMaistre CF; Craig FE; Meneghetti C; McMullin B; Parker K; Reuben J; Boldt DH; Rosenblum M; Woodworth T
    Cancer Res; 1993 Sep; 53(17):3930-4. PubMed ID: 8358720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The induction and suppression of in vitro IgG anti-tetanus toxoid antibody synthesis by human lymphocytes stimulated with tetanus toxoid in the absence of in vivo booster immunizations.
    Lum LG; Culbertson NJ
    J Immunol; 1985 Jul; 135(1):185-91. PubMed ID: 2582031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2.
    Zhang L; Waters C; Nichols J; Crumpacker C
    J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1181-7. PubMed ID: 1453329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.
    Bacha P; Williams DP; Waters C; Williams JM; Murphy JR; Strom TB
    J Exp Med; 1988 Feb; 167(2):612-22. PubMed ID: 3126255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis.
    Bacha P; Forte SE; Perper SJ; Trentham DE; Nichols JC
    Eur J Immunol; 1992 Jul; 22(7):1673-9. PubMed ID: 1623918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.
    Walz G; Zanker B; Brand K; Waters C; Genbauffe F; Zeldis JB; Murphy JR; Strom TB
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9485-8. PubMed ID: 2594781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.
    Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT
    Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia.
    Kiyokawa T; Shirono K; Hattori T; Nishimura H; Yamaguchi K; Nichols JC; Strom TB; Murphy JR; Takatsuki K
    Cancer Res; 1989 Jul; 49(14):4042-6. PubMed ID: 2786749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
    LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
    Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
    Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
    Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal models.
    Bacha P; Forte S; Kassam N; Thomas J; Akiyoshi D; Waters C; Nichols J; Rosenblum M
    Cancer Chemother Pharmacol; 1990; 26(6):409-14. PubMed ID: 2225311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DAB
    Bhopale MK; Hilliard B; Constantinescu CS; Phillips SM; Rostami A
    Immunopharmacol Immunotoxicol; 2017 Dec; 39(6):318-329. PubMed ID: 28929835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
    LeMaistre CF; Rosenblum MG; Reuben JM; Parkinson DR; Meneghetti CM; Parker K; Shaw JP; Deisseroth AB; Woodworth T
    Lancet; 1991 May; 337(8750):1124-5. PubMed ID: 1674015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis.
    Miller DD; Bach RG; Tio FO; Bailey SR; Waters CA; Woodworth TG; Nichols JC; Paige SB; Farrar M
    Atherosclerosis; 1996 Sep; 126(1):1-14. PubMed ID: 8879429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo.
    Kelley VE; Bacha P; Pankewycz O; Nichols JC; Murphy JR; Strom TB
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3980-4. PubMed ID: 3131768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.